High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap
- 1 June 1999
- journal article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 6 (6), 986-993
- https://doi.org/10.1038/sj.gt.3300937
Abstract
Recombinant adeno-associated virus type 2 (rAAV) vectors have recently been used to achieve long-term, high level transduction in vivo. Further development of rAAV vectors for clinical use requires significant technological improvements in large-scale vector production. In order to facilitate the production of rAAV vectors, a recombinant herpes simplex virus type I vector (rHSV-1) which does not produce ICP27, has been engineered to express the AAV-2 rep and cap genes. The optimal dose of this vector, d27.1-rc, for AAV production has been determined and results in a yield of 380 expression units (EU) of AAV-GFP produced from 293 cells following transfection with AAV-GFP plasmid DNA. In addition, d27.1-rc was also efficient at producing rAAV from cell lines that have an integrated AAV-GFP provirus. Up to 480 EU/cell of AAV-GFP could be produced from the cell line GFP-92, a proviral, 293 derived cell line. Effective amplification of rAAV vectors introduced into 293 cells by infection was also demonstrated. Passage of rAAV with d27. 1-rc results in up to 200-fold amplification of AAV-GFP with each passage after coinfection of the vectors. Efficient, large-scale production (>109 cells) of AAV-GFP from a proviral cell line was also achieved and these stocks were free of replication-competent AAV. The described rHSV-1 vector provides a novel, simple and flexible way to introduce the AAV-2 rep and cap genes and helper virus functions required to produce high-titer rAAV preparations from any rAAV proviral construct. The efficiency and potential for scalable delivery of d27.1-rc to producer cell cultures should facilitate the production of sufficient quantities of rAAV vectors for clinical application.This publication has 27 references indexed in Scilit:
- Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophiliaGene Therapy, 1998
- Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABAAα1 containing receptors and increases inferior collicular seizure sensitivityBrain Research, 1997
- Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectorsProceedings of the National Academy of Sciences of the United States of America, 1997
- Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promotersGene Therapy, 1997
- Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic proteinProceedings of the National Academy of Sciences of the United States of America, 1996
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- Mutagenesis of an AUG codon in the adeno-associated virus rep gene: Effects on viral DNA replicationVirology, 1989
- Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.Proceedings of the National Academy of Sciences of the United States of America, 1984
- The ParvovirusesPublished by Springer Science and Business Media LLC ,1984
- Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAVCell, 1983